ILP-2 modeling and virtual screening of an FDA-approved library: a possible anticancer therapy

Background/aim: The members of the inhibitors of apoptosis protein (IAP) family inhibit diverse components of the caspase signaling pathway, notably caspase 3, 7, and 9. ILP-2 (BIRC-8) is the most recently identified member of the IAPs, mainly interacting with caspase 9. This interaction would eventually lead to death resistance in the case of cancerous cells. Therefore, structural modeling of ILP-2 and finding applicable inhibitors of its interaction with caspase 9 are a compelling challenge. Materials and methods: Three main protein modeling approaches along with various model refinement measures were harnessed to achieve a reliable 3D model, using state-of-the-art software. Thereafter, the selected model was employed to perform virtual screening of an FDA approved library. Results: A model built by a combinatorial approach (homology and ab initio approaches) was chosen as the best model. Model refinement processes successfully bolstered the model quality. Virtual screening of the compound library introduced several high affinity inhibitor candidates that interact with functional residues of ILP2. Conclusion: Given the 3D structure of the ILP2 molecule, we found promising inhibitory molecules. In addition to high affinity towards the ILP2 molecule, these molecules interact with residues that play pivotal rules in ILP2-caspase interaction. These molecules would inhibit ILP2-caspase interaction and consequently would lead to reactivated cell apoptosis through the caspases pathway.

PDF

___

1. Nachmias B, Ashhab Y, Ben-Yehuda D. The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. Semin Cancer Biol 2004; 14: 231-243.
2. Wei Y, Fan T, Yu M. Inhibitor of apoptosis proteins and apoptosis. Acta Bioch Bioph Sin 2008; 40: 278-288.
3. Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 2004; 64: 7183-7190.
4. Chai J, Yan N, Huh JR, Wu JW, Li W, Hay BA, Shi Y. Molecular mechanism of Reaper-Grim-Hid-mediated suppression of DIAP1-dependent Dronc ubiquitination. Nat Struct Mol Biol 2003; 10: 892-898.
5. Verhagen AM, Coulson EJ, Vaux DL. Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs. Genome Biol 2001; 2: 3009.1-3009.10.
6. Xiang M, Zhou W, Gao D, Fang X, Liu Q. Inhibitor of apoptosis protein-like protein-2 as a novel serological biomarker for breast cancer. Int J Mol Sci 2012; 13: 16737-16750.
7. Saleem M, Qadir MI, Perveen N, Ahmad B, Saleem U, Irshad T. Inhibitors of apoptotic proteins: new targets for anticancer therapy. Chem Biol Drug Des 2013; 82: 243-251.
8. Khalili S, Jahangiri A, Borna H, Ahmadi Zanoos K, Amani J. Computational vaccinology and epitope vaccine design by immunoinformatics. Acta Microbiol Imm H 2014; 61: 285- 307.
9. Jahangiri A, Rasooli I, Gargari SLM, Owlia P, Rahbar MR, Amani J, Khalili S. An in silico DNA vaccine against Listeria monocytogenes. Vaccine 2011; 29: 6948-6958.
10. Jahangiri A, Rasooli I, Rahbar MR, Khalili S, Amani J, Zanoos KA. Precise detection of L. monocytogenes hitting its highly conserved region possessing several specific antibody binding sites. J Theor Biol 2012; 305: 15-23.
11. Khalili S, Rahbar MR, Dezfulian MH, Jahangiri A. In silico analyses of Wilms tumor protein to designing a novel multiepitope DNA vaccine against cancer. J Theor Biol 2015; 379: 66-78.
12. Mohammadpour H, Khalili S, Hashemi ZS. Kremen is beyond a subsidiary co-receptor of Wnt signaling: an in silico validation. Turk J Biol 2015; 39: 501-510
13. Kopp J, Schwede T. Automated protein structure homology modeling: a progress report. Pharmacogenomics 2004; 5: 405- 416.
14. Durrant JD, McCammon JA. Molecular dynamics simulations and drug discovery. BMC Biol 2011; 9: 71.
15. Nguyen M, Tan K, Madhusudhan M. CLICKtopologyindependent comparison of biomolecular 3D structures. Nucleic Acids Res 2011; 39: W24-W8.
16. Zhang Y, Skolnick J. TM-align: a protein structure alignment algorithm based on the TM-score. Nucleic Acids Res 2005; 33: 2302-2309.
17. Kar S, Roy K. How far can virtual screening take us in drug discovery? Expert Opin Drug Dis 2013; 8: 245-261.
18. Sun C, Cai M, Meadows RP, Xu N, Gunasekera AH, Herrmann J, Wu JC, Fesik SW. NMR structure and mutagenesis of the third Bir domain of the inhibitor of apoptosis protein XIAP. J Biol Chem 2000; 275: 33777-33781.
19. Chang MW, Lindstrom W, Olson AJ, Belew RK. Analysis of HIV wild-type and mutant structures via in silico docking against diverse ligand libraries. J Chem Inf Model 2007; 47: 1258-1262.
20. Inghirami G, Chiarle R, Simmons WJ, Piva R, Schlessinger K, Levy DE. New and old functions of STAT3: a pivotal target for individualized treatment of cancer. Cell Cycle 2005; 4: 1131.
21. Wilson R, Goyal L, Ditzel M, Zachariou A, Baker DA, Agapite J, Steller H, Meier P. The DIAP1 RING finger mediates ubiquitination of Dronc and is indispensable for regulating apoptosis. Nat Cell Biol 2002; 4: 445-450.
22. Kulathila R, Vash B, Sage D, Cornell-Kennon S, Wright K, Koehn J, Stams T, Clark K, Price A. The structure of the BIR3 domain of cIAP1 in complex with the N-terminal peptides of SMAC and caspase-9. Acta Crystallogr D 2008; 65: 58-66.
23. Schimmer A, Dalili S, Batey R, Riedl S. Targeting XIAP for the treatment of malignancy. Cell Death Differ 2006; 13: 179-188.